MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Johnson and Johnson

Geschlossen

BrancheGesundheitswesen

160.12 3.04

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

155.34

Max

160.62

Schlüsselkennzahlen

By Trading Economics

Einkommen

3.4B

Verkäufe

20M

23B

KGV

Branchendurchschnitt

28.643

63.778

EPS

2.04

Dividendenrendite

2.99

Gewinnspanne

15.235

Angestellte

138,100

EBITDA

652M

5.9B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+8.41% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.99%

2.39%

Nächstes Ergebnis

15. Apr. 2025

Nächstes Ex-Dividendendatum

19. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

32B

400B

Vorheriger Eröffnungskurs

157.08

Vorheriger Schlusskurs

160.12

Nachrichtenstimmung

By Acuity

31%

69%

84 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Johnson and Johnson Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. März 2025, 15:16 UTC

Wichtige Markttreiber

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

10. März 2025, 13:59 UTC

Wichtige Markttreiber

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

2. Apr. 2025, 12:49 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson Expects 2026 Earnings Dilution to Be Reduced to About 21c/Shr

2. Apr. 2025, 12:49 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson Expects Deal to Dilute Adj EPS by About 25c in 2025 >JNJ

2. Apr. 2025, 12:48 UTC

Akquisitionen, Fusionen, Übernahmen

J&J: Deal Expected to Accelerate 2025 Sales Growth by About 0.8% With About $700M in Incremental Sales >JNJ

2. Apr. 2025, 12:45 UTC

Akquisitionen, Fusionen, Übernahmen

J&J: Addition of CAPLYTA Strengthens Lineup of Therapies With $5 Billion+ Potential in Peak Yr Sales >JNJ

2. Apr. 2025, 12:44 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson: sNDA Submitted to FDA for CAPLYTA as Adjunctive Treatment for Major Depressive Disorder >JNJ

2. Apr. 2025, 12:44 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson Closes Landmark Intra-Cellular Therapies Acquisition to Solidify Neuroscience Leadership

1. Apr. 2025, 20:07 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

1. Apr. 2025, 16:09 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Tesla, Johnson & Johnson, Southwest, Delta, MicroStrategy, PVH, Newsmax, and More -- Barrons.com

1. Apr. 2025, 13:51 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Tesla, Johnson & Johnson, PVH, Southwest, Newsmax, and More -- Barrons.com

1. Apr. 2025, 12:15 UTC

Top News

Johnson & Johnson Stock Falls After Latest Talc Resolution Rejected -- Barrons.com

1. Apr. 2025, 11:37 UTC

Market Talk

Johnson & Johnson To Reverse $7 Billion of Talc Reserve -- Market Talk

1. Apr. 2025, 10:36 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Tesla, XPeng, PVH, Progress Software, J&J, Newsmax, Southwest, and More -- Barrons.com

1. Apr. 2025, 01:04 UTC

Top News

Johnson & Johnson's Third Bankruptcy Case for Talc Lawsuits Thrown Out -- WSJ

21. März 2025, 23:02 UTC

Akquisitionen, Fusionen, Übernahmen

Ranking the S&P 500s Most Defensive Stocks -- Barrons.com

21. März 2025, 13:35 UTC

Ergebnisse
Heiße Aktien

Stocks to Watch Friday: J&J, Nike, FedEx, Micron -- WSJ

14. März 2025, 09:30 UTC

Top News

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

7. März 2025, 01:00 UTC

Top News

Finance Executives Seek Stability Amid Erratic Tariff Shifts -- WSJ

18. Feb. 2025, 22:22 UTC

Top News

Johnson & Johnson Goes to Trial on Third Talc Bankruptcy Plan -- Update

14. Feb. 2025, 13:00 UTC

Top News

J&J's High Hopes for Heart-Rhythm Device Grounded by Safety Concerns -- WSJ

24. Jan. 2025, 07:00 UTC

Top News

Disasters Spawn New Businesses. The California Wildfires Will Do the Same. -- Barrons.com

22. Jan. 2025, 21:39 UTC

Ergebnisse

These Stocks Moved the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22. Jan. 2025, 19:41 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22. Jan. 2025, 17:38 UTC

Market Talk
Ergebnisse

J&J's Forex Headwind in Outlook Surprised Investors -- Market Talk

22. Jan. 2025, 16:48 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22. Jan. 2025, 14:51 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Ford, and More -- Barrons.com

22. Jan. 2025, 14:09 UTC

Top News
Ergebnisse

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

22. Jan. 2025, 13:04 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, J&J, Procter & Gamble, United, Travelers, and More -- Barrons.com

22. Jan. 2025, 12:47 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, J&J, Procter & Gamble, United, Agilysys, and More -- Barrons.com

Peer-Vergleich

Kursveränderung

Johnson and Johnson Prognose

Kursziel

By TipRanks

8.41% Vorteil

12-Monats-Prognose

Durchschnitt 168.42 USD  8.41%

Hoch 185 USD

Tief 152 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Johnson and Johnson – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

14 ratings

6

Buy

8

Halten

0

Sell

Technischer Score

By Trading Central

153.13 / 164.36Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

84 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.